Implantable Defibrillator Therapy: A Clinical Guide (Developments in Cardiovascular Medicine, 244)

★★★★★ 4.9 127 reviews

US$68.00
Price when purchased online
Free shipping Free 30-day returns

Sold and shipped by www.quaproperties.com
We aim to show you accurate product information. Manufacturers, suppliers and others provide what you see here.
US$68.00
Price when purchased online
Free shipping Free 30-day returns

How do you want your item?
You get 30 days free! Choose a plan at checkout.
Shipping
Arrives Jul 4
Free
Pickup
Check nearby
Delivery
Not available

Sold and shipped by www.quaproperties.com
Free 30-day returns Details

Product details

Management number 231842287 Release Date 2026/06/18 List Price US$68.00 Model Number 231842287
Category

Implantable defibrillators as originally conceived by Michel Mirowski were limited to the detection and automatic termination of ventricular fibrillation. In the original "AID" device, the detection algoritlun sought to distinguish sinus rhytlun from ventricular fibrillation by identifying the "more sinusoidal waveform of ventricular fibrillation. " The therapeutic intervention was elicited only once deadly polymorphic rhythms had developed. It was rapidly learned, however, that ventricular fibrillation is usually preceded by ventricular tachycardia. Mirowski recognized the pivotal importance of developing algoritllms based on heart rate. Ventricular tachycardia detection allowed the successful development of interventions for the termination of ventricular tachyarrhythmias before they degenerated into ventricular fibrillation. Current device therapy no longer confines itself to tlle termination of chaotic rhythms but seeks to prevent them. Diagnostic algorithms moved upward along the chain of events leading to catastrophic rhytlulls. Rate smoothing algorithms were developed to prevent postextrasystolic pauses from triggering ventricular and atrial tachyarrhytlmlias. Beyond the renaissance of ectopy-centered strategies, long-term prevention received increasing attention. Multisite pacing therapies provided by "Arrhythmia Management Devices" were designed to reduce the "arrhytlunia burden" and optimize the synergy of cardiac contraction and relaxation. Clinical evidence now suggests that atrial fibrillation prevention by pacing is feasible and tllat biventricular pacing may be of benefit in selected patients with heart failure. However, these applications of device therapy that generally require ventricular defibrillation backup remain investigational and were not considered in this book. Read more

ISBN10 1402071434
ISBN13 978-1402071430
Edition 2002nd
Language English
Publisher Springer
Dimensions 6.5 x 1.1 x 9.68 inches
Item Weight 1.85 pounds
Print length 420 pages
Part of series Developments in Cardiovascular Medicine
Publication date August 31, 2002

Correction of product information

If you notice any omissions or errors in the product information on this page, please use the correction request form below.

Correction Request Form

Customer ratings & reviews

4.9 out of 5
★★★★★
127 ratings | 52 reviews
How item rating is calculated
View all reviews
5 stars
89% (113)
4 stars
1% (1)
3 stars
0% (0)
2 stars
0% (0)
1 star
10% (13)
Sort by

There are currently no written reviews for this product.